ANGPT2 and neoplasm: High pre-therapeutic Ang2 expression in the tumour vasculature was associated with a 15-percentage point increase in clinical benefit rate (CBR; partial response (PR) + stable disease (SD)) to sunitinib, when the high and low Ang2 categories were compared (CBR was 91% in the Ang2 high category vs 76% in Ang2 low category, Fisher’s exact test, P = 0.033) (Fig 2C and 2D).